TMRW, the creator of the first Robotic Process Automation (RPA) platform specifically designed for in vitro fertilization (IVF) has commenced a multi-site study to test its platform in a live clinical environment. The study has been launched in partnership with six leading clinics around the country. The study will test the platform in real-time – measuring improvements achieved through automation and allowing for instant iteration of platform technology.
"As access to IVF therapies grows globally, it's absolutely imperative that embryo preservation evolves past the 40-year-old technology used in fertility medicine," said Dr. Jeff Port, TMRW's co-founder and Chief Medical Officer. "We anticipate 200-300 million IVF births this century, of which the majority will be associated with cells that were once frozen. TMRW's automated cryopreservation process performs up to 17,000 'health checks' daily to establish the perfect storage environment. Our platform is customized to meet this surging demand while reducing risk and providing peace of mind that both physicians and their patients justifiably seek."
TMRW's state-of-the-art platform was designed to mitigate human error and monitor the environment of frozen embryos and eggs around the clock. The platform replaces current analog IVF cryopreservation and tissue management system, by implementing automated cryomanagement and RFID-enabled digital chain of custody for embryos and gametes.
Cryopreservation is the process of freezing biological material at extreme temperatures; most common -196 degrees Celsius in liquid nitrogen. At these low temperatures, all biological activity stops, including the biochemical reactions that lead to cell death and DNA degradation. This preservation method in theory makes it possible to store living cells as well as other biological material unchanged for centuries.
Already experiencing rapid market enthusiasm, TMRW is poised to become the global standard for cryo-preservation and fertility cell management. IVF clinicians have embraced the concept of TMRW's risk-mitigating RPA platform as a replacement for current less sophisticated analog IVF cryo-management systems.
Photo: Diligent Robotics
Based on the article by Yahoo Finance